Mylan NV (MYL)

43.03
NASDAQ : Health Care
Prev Close 42.85
Day Low/High 42.63 / 43.98
52 Wk Low/High 37.59 / 55.51
Avg Volume 5.10M
Exchange NASDAQ
Shares Outstanding 534.91M
Market Cap 22.92B
EPS 1.80
P/E Ratio 26.78
Div & Yield N.A. (N.A)

Latest News

Black Rock Pharmacy Co-Owner Arthur To CNBC: 'There's a Huge Issue With PBMs'

Black Rock Pharmacy Co-Owner Arthur To CNBC: 'There's a Huge Issue With PBMs'

Pharmacy Benefit Managers (PBMs) 'operate within a sphere of secrecy,' Black Rock Pharmacy co-owner Brad Arthur told CNBC.

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.

Mylan, Trump and Tons of Huge Corporations Have Donated to the Clinton Foundation

Mylan, Trump and Tons of Huge Corporations Have Donated to the Clinton Foundation

Pretty much every company you can think of has donated to the Clinton Foundation. So has Donald Trump. Should it matter?

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

The recent harsh spotlight on the sector raises the question.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

Wall Street will look to comments from Fed Chair Janet Yellen on interest rates; futures are higher; Carl Icahn recently discussed selling his stake in Herbalife, a report says.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

Mylan (MYL) CEO Heather Bresch Needs To Explain EpiPen Price Hike, Senator Grassley Tells CNBC

Mylan (MYL) CEO Heather Bresch Needs To Explain EpiPen Price Hike, Senator Grassley Tells CNBC

Iowa Senator Charles Grassley said he'll have the conversation Mylan (MYL) CEO Heather Bresch has asked him for once she answers his letter.

Wall Street Hesitates Ahead of Yellen's Speech on Friday

Wall Street Hesitates Ahead of Yellen's Speech on Friday

The anticipation for Friday's speech from Federal Reserve Chair Janet Yellen left investors hesitant on Thursday.

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

The company is under public scrutiny, and has lost more than 12% of its share price so far this week.

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

More competition in the drug industry would prevent situations like the big price hike in Mylan's EpiPens, according to Jim Cramer.

Stocks Break Lower in Choppy Trade on Fed Jitters

Stocks Break Lower in Choppy Trade on Fed Jitters

Stocks break into the red by mid-afternoon Thursday after a choppy morning as Federal Reserve members head to Jackson Hole, Wyo., for their closely watched summer summit.

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Competition could be the cure, not demonizing the drugmaker's CEO.

Mylan EpiPen Scrutiny Puts More Biotechs at Risk

Mylan EpiPen Scrutiny Puts More Biotechs at Risk

Biotech and pharma stocks have been hit hard under pressure from Hillary Clinton and Congress. What's next?

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

After Mylan raised the price of its EpiPen by 400 percent, sparking a wave of controversy, the company now saying it will offer a savings card worth $300 to users.

Mylan's Mistake: Making Money?

Mylan's Mistake: Making Money?

Technical evidence shows bigger issues are at play at the EpiPen maker.

Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem

Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem

The pharmaceutical company announced that it will increase its patient assistance program in hopes of quelling a growing backlash over its drug pricing.

Stocks Fluctuate as Fed Members Head to Jackson Hole

Stocks Fluctuate as Fed Members Head to Jackson Hole

Stocks fluctuate on Thursday morning as Federal Reserve members head to Jackson Hole, Wyo., for their closely watched summer summit.

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Short-seller Andrew Left says Mallinckrodt has long been gaming the system on its Acthar Gel drug.

More Squawk from Jim Cramer: Mylan (MYL) Should Have More Competition

More Squawk from Jim Cramer: Mylan (MYL) Should Have More Competition

Mylan (MYL) said on Thursday that it would reduce the out-of-pocket cost of its EpiPens, which treat life-threatening allergies.

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. stocks moved slightly lower on Thursday as investors anxiously await remarks from Federal Reserve Chair Janet Yellen on Friday.

Mylan EpiPen Controversy Puts More Biotechs in Danger

Mylan EpiPen Controversy Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

'No One Is More Frustrated Than Me,' Mylan (MYL) CEO Heather Bresch Tells CNBC

'No One Is More Frustrated Than Me,' Mylan (MYL) CEO Heather Bresch Tells CNBC

Mylan (MYL) CEO Heather Bresch told CNBC that the price increase is a result of changing healthcare insurance plans.

Mylan Dispute Puts More Biotechs in Danger

Mylan Dispute Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Stock Futures Head Lower as Jobless Claims Decline, Durable Goods Increase

Stock Futures Head Lower as Jobless Claims Decline, Durable Goods Increase

Stock futures move lower on Thursday morning as monetary policy officials head to Jackson Hole, Wyo., for their two-day summer summit.

Mallinckrodt's Top Drug Could Go the Way of EpiPen

Mallinckrodt's Top Drug Could Go the Way of EpiPen

The drug that's helping boost the company's stock could become its biggest risk.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

The Fed meets for a monetary policy summit, and investors consider dollar-store earnings and jobless claim numbers.

Morning Movers: SHLD, TIF, DG, DLTR, MYL

Morning Movers: SHLD, TIF, DG, DLTR, MYL

The discount dollar stores quarterly results disappoint, while Tiffany beats profit forecasts.

Rev's Forum: Market Resets, Waiting for Janet Yellen

Rev's Forum: Market Resets, Waiting for Janet Yellen

The indexes' positive tone shifted in the last two days.